Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Lisinopril 20mg Formulations
NCT05061901Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lisinopril in hypertension (HTN) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Curve from time 0 to last measurable concentration at 72 hours. Started Oct 2021; status: completed.
02
Drugs
lisinopril
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05061901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061901.